ArticleNPJ precision oncology2022
Locoregional tumor burden and risk of mortality in metastatic breast cancer.
Article in NPJ precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Global determinants of breast cancer mortality: a comprehensive meta-analysis of clinical, demographic, and lifestyle risk factors.BMC public health · 2025Pooled it
- HIV-related stigma and associated factors: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Metastatic presentation of breast cancer in India: evidence from national cancer registry (2009-2020).The Lancet regional health. Southeast Asia · 2026Article
- Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis.Frontiers in oncology · 2026Article
- Article
- Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer.Exploration of targeted anti-tumor therapy · 2026Review
- Machine learning-based prognostic model for metastatic breast cancer and its interpretability: a multicenter retrospective study.Gland surgery · 2025Article
- Article
- Breast cancer treatment modalities, treatment delays, and survival in Brunei Darussalam.BMC cancer · 2025Article
- Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.Frontiers in nutrition · 2025Article
- Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy.Thoracic cancer · 2024Article
- Elacestrant plus alpelisib in anTherapeutic advances in medical oncology · 2024Article
- Patterns ofFrontiers in endocrinology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The role of lymph node involvement and tumor size in metastatic disease including breast cancer is unclear. Here, nodal metastasis and T stage on the risk of mortality were investigated in de novo metastatic breast cancer population (35812 patients) in the Surveillance, Epidemiology, and End Results (SEER) Program database in the United States. We found an association between all-cause mortality and regional node involvement (adjusted hazard ratio [HR] = 1.45, 95% confidence interval [CI] 1.36-1.55, p < 0.0001) or T stage (HR = 1.20, 95% CI 1.14-1.25, p < 0.0001), independent of known clinicopathologic measurements. Number of positive nodes, and size and chest wall involvement of the breast tumors exhibited similar significance for breast cancer-specific mortality in the population (p < 0.0001 each), and all-cause mortality in hormone receptor (HR)-positive/HER2-negative (HR
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.